尊龙凯时·「中国区」官方网站

2023-10-11 [BIOVOX] eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focussed on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

2023-10-11 [Endovascular Today] Sirtex Medical’s SIR-Spheres Y-90 ResinMicrospheres Approved in China

2023-10-11 [OncLive] Leveraging SIR-Spheres® Y-90 Resin Microspheres from Sirtex Medical to Improve Outcomes in Metastatic CRC

2023-10-11 [businesswire] ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area

2023-10-11 [GriffithNews] Griffith and China Grand Pharma Sign Landmark Deal to Develop New Drug for Parainfluenza Virus

2023-10-11 [PRNewswire] Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19

2020-05-08 The COVID-19 Drug R&D Discovery Grandpharma’s Sepsis Syndrome Innovative Drug Eligible for Clinical Study

2020-03-31 Grandpharma gets sepsis innovative medicine again